The choice between a ritonavir-boosted protease inhibitor- and a non-nucleoside reverse transcriptase inhibitor-based regimen for initiation of antiretroviral treatment - results from an observational study in Germany.
about
The choice between a ritonavir-boosted protease inhibitor- and a non-nucleoside reverse transcriptase inhibitor-based regimen for initiation of antiretroviral treatment - results from an observational study in Germany.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 30 December 2016
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
The choice between a ritonavir ...... bservational study in Germany.
@en
The choice between a ritonavir ...... bservational study in Germany.
@nl
type
label
The choice between a ritonavir ...... bservational study in Germany.
@en
The choice between a ritonavir ...... bservational study in Germany.
@nl
prefLabel
The choice between a ritonavir ...... bservational study in Germany.
@en
The choice between a ritonavir ...... bservational study in Germany.
@nl
P2093
P2860
P1476
The choice between a ritonavir ...... bservational study in Germany.
@en
P2093
Alexander Kuhlmann
Hans Heiken
Johannes Bogner
Jörg Mahlich
Matthias Stoll
P2860
P2888
P356
10.1186/S40545-016-0092-4
P577
2016-12-30T00:00:00Z
P6179
1002095191